Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Luis Castilla, Press Officer, Public Citizen’s Texas office
w. (512) 637-9467

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


March 2, 2011

Misleading Communications Regarding Breast Implant-Related Cancer to Be Removed From Websites of Leading Plastic Surgery Organizations

Statement of Dr. Michael Carome, Deputy Director, Public Citizen’s Health Research Group

 The Food and Drug Administration (FDA) has taken laudable action by prompting two leading plastic surgery associations to remove misleading information regarding breast implant-related cancer from the organizations’ websites.

In a Feb. 17 letter to the FDA, Public Citizen alerted the agency that the presidents of two leading plastic surgery organizations – the American Society of Plastic Surgeons (ASPS) and the American Society for Aesthetic Plastic Surgery (ASAPS) – urged members to inaccurately downplay the significance of recent evidence about the risks of breast implant-related cancer when speaking to female patients during a recent members-only webinar posted on the ASPS and ASAPS websites. Such communications represented a deplorable attempt to trivialize the significance of the findings of increased numbers of cases of a rare form of cancer, called anaplastic large cell lymphoma (ALCL), in women with breast implants. Public Citizen called on the FDA to stop this deliberately misleading messaging campaign, the goal of which apparently was to keep women in the dark about the dangers of breast implants so they will continue to ask for them.

In a response letter written Feb. 28 and received today by Public Citizen, Dr. Jeffrey Shuren, the director of the FDA’s Center for Devices and Radiological Health, informed Public Citizen that after the FDA reviewed the ASPS/ASAPS webinar and spoke with representatives of both organizations, ASPS and ASAPS now plan to remove the misleading webinar from their websites.

In his letter, Dr. Shuren noted that while ASPS and ASAPS are independent organizations that FDA does not regulate, FDA is committed to assuring that health care providers and patients receive accurate information about the possible association between breast implants and the development of ALCL. Removal of the webinar from the ASPS and ASAPS websites is an important first step in undoing the misleading and inaccurate “educational” campaign initiated by these organizations.

Among the misleading claims made during the ASPS/ASAPS webinar was that the type of cancer seen in breast implant patients had a “benign course” and that “surgery [to treat the cancer] was curative.” However, as Dr. Shuren stated in his letter, “the optimal treatment regimen [for breast implant-associated ALCL] has not been established and … additional data collection is needed to fully understand … [its] risk factors, optimal treatment plan, and prognosis.”

The FDA plans to collaborate with ASPS and other experts in the clinical and scientific communities to develop a registry to gather additional information to better characterize ALCL in women with breast implants.

As the FDA moves forward with these plans, it is essential that the agency closely monitors the control of the registry to ensure that the integrity of the data being collected is not corrupted by those with significant conflicts of interest.


Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.